Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 15;11:18330. doi: 10.1038/s41598-021-97406-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

K_Ca1.1 channel blockade potentiates the inhibitory effect of erlotinib on migration of A549-3R cells. (A) Trajectories of individual A549-3R cells migrating under control conditions (left panel; n = 59) or in the presence of 10 µmol/L paxilline (right panel; n = 60). Cell paths are normalized to common starting points and the grey circles represent the mean translocations covered during the course of the experiment. (B) Summary of the migration experiments in which we probed the contribution of K_Ca1.1 channels with paxilline (pax; 10 µmol/L) under control conditions (con; left part of the panel) and in combination with erlotinib (erl; right part of the panel; N/n = 3/30 for each condition). (C) Cumulative translocation binned in 1 h intervals of A549-3R cells migrating under control conditions and in the presence of paxilline and erlotinib. (D) The directionality of A549-3R cells is reduced in the presence of paxilline and erlotinib.